Skip to main content
ViatrisLinkedIn

Viatris presents two Phase 2 SLE trial analyses at ACR2026 on November 8.

Source: Autobound Signal API · 76 signals tracked for Viatris · updated

Get Viatris' live signals in Claude or ChatGPT, or by API

AskWhat changed at Viatris this week? Use Autobound signals for viatris.com.

Source

LinkedInNov 7, 2026
likes
64
comments
1

Post

There is still much to understand about systemic lupus erythematosus (SLE) and the immune processes involved in this disease. At #ACR2026, we are presenting two analyses from the placebo-controlled Phase 2 trial for an investigational asset as part of our commitment to deepening scientific understanding of SLE. 👉 Explore abstracts 0259 and 0285: Nov. 8 | 10:30 a.m.-12:30 p.m. ET | Location: WB1&2 https://cdmcd.co/xK9vrZ https://cdmcd.co/YK6q7R

linkedin.com/posts/viatris_viatris-at-acr-2026-activity-7524788244853...Read the full source

Extracted by Autobound

From the Signal API record
Signal
LinkedIn

What this signalsCompany posts often show what the team is pushing right now.

More LinkedIn signals at other companies

The full record

From the Signal API record

Topics and mentions

Tags

  • Medical Research
  • Events

Initiatives

  • presenting SLE trial results at ACR2026

Extraction

Detected
Nov 7, 2026
signal_type
linkedin-post-company
signal_subtype
linkedinPost

Use this data

Get every LinkedIn signal for Viatris and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Viatris this week?”

  2. Send it to your own tools

    The Signal API returns LinkedIn signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full linkedin-post-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/2890540f-fed8-4492-b573-f3af09ca9eba returns this record as JSON. POST /v1/companies/enrich returns every signal for viatris.com.

{
  "signal_id": "2890540f-fed8-4492-b573-f3af09ca9eba",
  "signal_type": "linkedin-post-company",
  "signal_subtype": "linkedinPost",
  "detected_at": "2026-11-07T11:02:01.377+00:00",
  "company": {
    "name": "Viatris",
    "domain": "viatris.com"
  },
  "data": {
    "tags": [
      "Medical Research",
      "Events"
    ],
    "summary": "Viatris presents two Phase 2 SLE trial analyses at ACR2026 on November 8.",
    "post_url": "https://www.linkedin.com/posts/viatris_viatris-at-acr-2026-activity-7524788244853473280-sqJ_",
    "num_likes": 64,
    "post_text": "There is still much to understand about systemic lupus erythematosus (SLE) and the immune processes involved in this disease. \r\n \r\nAt #ACR2026, we are presenting two analyses from the placebo-controlled Phase 2 trial for an investigational asset as part of our commitment to deepening scientific understanding of SLE. \r\n \r\n👉 Explore abstracts 0259 and 0285: Nov. 8 | 10:30 a.m.-12:30 p.m. ET | Location: WB1&2 \r\nhttps://cdmcd.co/xK9vrZ\r\nhttps://cdmcd.co/YK6q7R",
    "initiatives": [
      {
        "topic": "presenting SLE trial results at ACR2026",
        "urgency": 0.7
      }
    ],
    "posted_date": "2026-11-07T11:02:01.377Z",
    "num_comments": 1
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.